GC Green Cross CEO Euncheol Heo: "Aliglo FDA Approval a Milestone... We Must Prepare for a 'Time of Proof'"

Euncheol Heo, CEO of GC Green Cross, who achieved the milestone of obtaining U.S. approval for the blood product “Aliglo” last year, expressed his gratitude to employees in his New Year’s address, while also urging them to prepare for what he called a “time of proof.”

Euncheol Heo, CEO of GC Green Cross
Photo by GC Green Cross

In his New Year’s address on January 2, Heo stated, “2023 was a year marked by both challenges and moments of joy. Even amid the crisis of stagnant sales, our unique perseverance and capabilities enabled us to meet global standards and achieve the remarkable feat of securing U.S. FDA approval for Aliglo.”

He continued, “I have realized that I am more grateful for what we have learned and gained through failures and setbacks than for the joy of success after eight years of effort. I am thankful that we have dedicated and responsible GC employees; that our uncompromising pursuit of ‘difficult-to-make but essential medicines’ has proven to be the right path; and that we are now moving from a period of potential to a time of proof.”

Heo described the upcoming period as a “time of proof,” as the company plans to begin selling Aliglo in the U.S. through its local subsidiary, GC Biopharma USA, starting in the second half of this year. He added, “During the time of potential, mistakes and failures served as medicine and experience, but in the time of proof, mistakes will mean outright failure. We will prepare every step thoroughly and flawlessly.”

Finally, Heo emphasized, “I am very pleased that we can begin the New Year with the excitement of global expansion. As the protagonists of GC-a small but strong company, a company with the heart of youth, and a global company proving its potential-let us move forward into the global market with even greater responsibility and a strong sense of mission.”